Please be advised that EMVDA has its own web site www.emvda.org.

The goal of this 5-year project is to systematically develop and test malaria vaccines by comparative and continuous evaluation of candidates. Exploiting the capabilities of 2 SMEs, 8 European malaria vaccine research centres, the European Malaria Vaccine Initiative (EMVI) and African Partner Groups already linked through the African Malaria Network (AMANET), we will select and promote the development of the best candidates from a group of projects in a candidate development pipeline that reaches from antigen validation and the creation of a vaccine development rationale to early proof-of-principle clinical trials.

Our key goal is to identify specific parasite antigens that have potential for development as candidate vaccines and move these as quickly as possible to clinical studies. Inherent in this concept is that there are clear criteria for progression.

The project is organised in 6 Work Package Groups:
1. Candidate Antigens;
2. Platforms and Adjuvants;
3. Vaccine Development Cross-cutting Issues (including assays for vaccine evaluation);
4. Demonstration activities including GMP production and phase 1 and phase 2a trials;
5. Training, Integration & Partnership Activities and
6. Management Activities comprising both consortium management and product development management.

In summary, the EMVDA brings together Europe’s leading malaria vaccine researchers and pan-Union initiatives in an unprecedented collaboration with vaccine SMEs to drive the production and clinical development of an effective vaccine to protect those vulnerable to this disease and thus aid human development.